Largest Randomized Trial Evaluates Steroids for Infant Heart Surgery
Less complex heart patients may benefit, but not without risk
Chest Pain Patients Benefit from Precision Diagnostic Testing Approach
A study comparing two approaches for diagnosing heart disease found that a risk analysis strategy is superior to the usual approach of immediately performing functional tests or catheterization for low- to intermediate-risk patients with new-onset chest pain.
Comparative Study of Two Heart Failure Drugs Finds No Difference in Outcomes
In a head-to-head comparison of two so-called ‘water pills’ that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths,
Study Finds No Benefit to Taking Fluvoxamine for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the
Out of the Hospital, Not Out of the Woods
New research shows COVID-19 patients have a higher likelihood of heart failure post-discharge
A Win-Win: DCRI study shows pulmonary rehab in COPD patients reduces health care costs while improving patient health
Pulmonary rehabilitation is an important evidenced-based treatment to improve health and quality of life for people living with Chronic Obstructive Pulmonary Disease (COPD). Now, new research from the Duke Clinical Research Institute has shown that the benefits of pulmonary rehabilitation are likely to extend beyond the patient to reduce costs for the health care system as well – with an estimated savings of more than $5,000 per patient.
IMPACT-AFib study shows a mailer not enough to increase blood thinner use in AF patients
If you want to change patient and provider behavior to improve a patient’s health, will an informational mailer make a difference?
Immune modulator drugs improved survival for people hospitalized with COVID-19
A large randomized, placebo-controlled clinical trial led by the National Institutes of Health with support from the Duke Clinical Research Institute shows that treating adults hospitalized with COVID-19 with infliximab or abatacept – drugs widely used to treat certain autoimmune diseases – substantially improved clinical status and reduced deaths.
DCRI faculty member develops H. pylori Quality Measure to Reduce Rates of Failed Eradication
A recent paper from Duke Clinical Research Institute (DCRI) faculty on behalf of the American Gastroenterological Association (AGA) provides new tools for health care providers treating patients wi
Stroke Patients’ Rates of Declining Thrombolysis Show Race-Ethnic Disparities
A new study set out to determine the prevalence of tPA declination in a nationwide registry of acute ischemic stroke (AIS) patients and to investigate differences in declination by race-ethnicity. The results appear in a paper in the February 28 issue of Neurology entitled ‘Race-Ethnic Disparities in Rates of Declination of Thrombolysis for Stroke.’